Skip to main content
Download PDF
- Main
The Overall Survival Benefit in EV-302: Is Enfortumab Vedotin plus Pembrolizumab the New Frontline Standard of Care for Metastatic Urothelial Carcinoma?
Published Web Location
https://doi.org/10.1016/j.euo.2024.02.010Main Content
For improved accessibility of PDF content, download the file to your device.
If you recently published or updated this item, please wait up to 30 minutes for the PDF to appear here.
Enter the password to open this PDF file:
File name:
-
File size:
-
Title:
-
Author:
-
Subject:
-
Keywords:
-
Creation Date:
-
Modification Date:
-
Creator:
-
PDF Producer:
-
PDF Version:
-
Page Count:
-
Page Size:
-
Fast Web View:
-
Preparing document for printing…
0%